
PACB Stock Forecast & Price Target
PACB Analyst Ratings
Bulls say
Pacific Biosciences of California Inc. has shown promising trends in the placement and utilization of its Revio sequencing platform, contributing positively to its near-term guidance and long-term targets. The company’s management expresses confidence in returning to growth this year, supported by a strong organic profile and recent strategic acquisitions. Additionally, the potential for future mergers and acquisitions may enhance its market position, despite a cautious outlook in light of the uncertain macroeconomic environment.
Bears say
Pacific Biosciences of California Inc faces a challenging financial outlook due to stagnant utilization rates and weaker-than-expected demand for its new instruments, which jeopardizes its 2026 financial targets. Furthermore, persistent demand weakness in key markets like China, coupled with tightening research budgets and diminished funding for the life sciences sector, threatens the company's growth potential. Additionally, increased competitive pressures could result in a loss of market share, further adversely affecting the company's financial results.
This aggregate rating is based on analysts' research of Pacific Biosciences of California and is not a guaranteed prediction by Public.com or investment advice.
PACB Analyst Forecast & Price Prediction
Start investing in PACB
Order type
Buy in
Order amount
Est. shares
0 shares